Pasithea Therapeutics

Pasithea Therapeutics Quick Ratio

The Quick Ratio (Acid Test) of Pasithea Therapeutics (KTTA) as of Nov 21, 2026 is 11.35. In the previous year, Quick Ratio (Acid Test) was 3.29 — a change of 245.03% (higher).

Quick Ratio

11.35

YoY

245.03%

Last updated:

Quick Ratio (Acid Test) of Pasithea Therapeutics is 2025 11.35 . Quick Ratio (Acid Test) of Pasithea Therapeutics was 2024 3.29 . It decreases by 245.03% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pasithea Therapeutics Stock analysis

What does Pasithea Therapeutics do? Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics. Pasithea Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pasithea Therapeutics stock

Quick Ratio (Acid Test) of Pasithea Therapeutics is 11.35 in 2025.

Quick Ratio (Acid Test) of Pasithea Therapeutics changed from 3.29 to 11.35, representing a 245.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Pasithea Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Pasithea Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Pasithea Therapeutics

All Key Metrics — Pasithea Therapeutics